Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Secukinumab - Novartis

Drug Profile

Secukinumab - Novartis

Alternative Names: AIN-457; Anti-interleukin 17A monoclonal antibody; Cosentyx; KB-03303A; Kosentikusu; NVP-AIN-457; Scapho

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alcon; Novartis
  • Developer Beth Israel Deaconess Medical Center; GWT-TUD GmbH; Icahn School of Medicine at Mount Sinai; Novartis
  • Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-radiographic axial spondyloarthritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Hidradenitis suppurativa; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Registered Juvenile rheumatoid arthritis
  • Phase III Giant cell arteritis; Graves ophthalmopathy; Polymyalgia rheumatica; Rotator cuff injuries
  • Phase II Atopic dermatitis; Discoid lupus erythematosus; Necrobiosis lipoidica; SARS-CoV-2 acute respiratory disease; Tendon injuries
  • Discontinued Alopecia areata; Asthma; Crohn's disease; Dry eyes; Lichen planus; Lupus nephritis; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus; Uveitis

Most Recent Events

  • 15 Mar 2024 Phase-I clinical trials in Giant cell arteritis in USA (IV) (NCT06130540)
  • 15 Mar 2024 Phase-I clinical trials in Polymyalgia rheumatica in USA (IV) (NCT06130540)
  • 06 Feb 2024 Novartis plans to file a regulatory submission for Polymyalgia rheumatica in 2026 (Novartis pipeline, February 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top